Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer

NCT01932697 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01932697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01932697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
September 4, 2013
Completion date
December 28, 2021
Enrollment
81 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus infection, stage i oropharyngeal squamous cell carcinoma, stage ii oropharyngeal squamous cell carcinoma, stage iii oropharyngeal squamous cell carcinoma, stage iva oropharyngeal squamous cell carcinoma, stage ivb oropharyngeal squamous cell carcinoma